Texas Permanent School Fund Corp raised its stake in shares of DaVita Inc. (NYSE:DVA – Free Report) by 1.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,993 shares of the company’s stock after buying an additional 142 shares during the period. Texas Permanent School Fund Corp’s holdings in DaVita were worth $1,104,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Commonwealth Equity Services LLC boosted its stake in shares of DaVita by 48.4% during the 1st quarter. Commonwealth Equity Services LLC now owns 38,997 shares of the company’s stock valued at $3,163,000 after buying an additional 12,726 shares during the period. KBC Group NV raised its holdings in shares of DaVita by 73.8% during the 1st quarter. KBC Group NV now owns 45,299 shares of the company’s stock valued at $3,674,000 after purchasing an additional 19,228 shares in the last quarter. Bessemer Group Inc. raised its holdings in shares of DaVita by 55.1% during the 1st quarter. Bessemer Group Inc. now owns 445 shares of the company’s stock valued at $36,000 after purchasing an additional 158 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of DaVita by 176.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 13,086 shares of the company’s stock valued at $1,315,000 after purchasing an additional 8,347 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of DaVita by 146.1% during the 2nd quarter. Victory Capital Management Inc. now owns 6,100 shares of the company’s stock valued at $613,000 after purchasing an additional 3,621 shares in the last quarter. Institutional investors and hedge funds own 84.69% of the company’s stock.
DaVita Stock Performance
NYSE DVA opened at $96.16 on Monday. The company has a debt-to-equity ratio of 6.01, a current ratio of 1.24 and a quick ratio of 1.19. The firm has a market capitalization of $8.78 billion, a price-to-earnings ratio of 14.75, a P/E/G ratio of 0.63 and a beta of 0.98. The company’s fifty day moving average is $87.82 and its two-hundred day moving average is $95.86. DaVita Inc. has a 52-week low of $69.45 and a 52-week high of $116.97.
In other news, insider Kathleen Alyce Waters sold 9,794 shares of DaVita stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $101.81, for a total transaction of $997,127.14. Following the sale, the insider now directly owns 81,297 shares in the company, valued at approximately $8,276,847.57. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.40% of the stock is owned by company insiders.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the stock. TheStreet downgraded shares of DaVita from a “b-” rating to a “c” rating in a report on Monday, October 23rd. UBS Group cut their price target on shares of DaVita from $142.00 to $113.00 and set a “buy” rating on the stock in a report on Friday. StockNews.com began coverage on shares of DaVita in a report on Thursday, October 5th. They issued a “buy” rating on the stock. Finally, Truist Financial dropped their target price on shares of DaVita from $115.00 to $104.00 and set a “hold” rating on the stock in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.67.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
- Five stocks we like better than DaVita
- Conference Calls and Individual Investors
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Learn Technical Analysis Skills to Master the Stock Market
- MarketBeat Week in Review – 11/13 – 11/17
- Consumer Discretionary Stocks Explained
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.